✦ LIBER ✦

182 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: Results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow-up

✍ Scribed by D. McLeod; P. Iversen; W. See; M. Wirth; K. Carroll; C. Morris; T. Morris

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

181 Bicalutamide (‘Casodex’) 150 mg as a

✍ M. Wirth; P. Iversen; D. McLeod; W. See; C. Morris; T. Morris; K. Carroll 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 237 KB

Bicalutamide (‘Casodex’) 150 Mg as adjuv

✍ R.O. Fourcade; I. Klimberg; W.A. See; M.P. Wirth; D.G. McLeod; P. Iversen; I. Ga 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 200 KB

180 Bicalutamide (‘Casodex’) 150 mg in a

✍ P. Iversen; D. McLeod; W. See; M. Wirth; T. Morris; C. Morris; K. Carroll 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 219 KB

Bicalutamide (‘Casodex’) 150 mg as

✍ Chris J. Tyrrell; Heather Payne; William A. See; David G. McLeod; Manfred P. Wir 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 245 KB